2025
ICD-10-CM
Section

E70-E88 Metabolic disorders

  • Non-billable
  • 2016–2025

Type 1 excludes

  • Androgen insensitivity syndrome (E34.5-)

  • Congenital adrenal hyperplasia (E25.0)

  • Hemolytic anemias attributable to enzyme disorders (D55.-)

  • Marfan syndrome (Q87.4-)

  • 5-alpha-reductase deficiency (E29.1)

Type 2 excludes

  • Ehlers-Danlos syndromes (Q79.6-)

Codes

Versions

  1. 2025

    No changes

  2. 2024

    Code changed

    • Type 1 excludes

        • androgen insensitivity syndrome (E34.5-)
        • congenital adrenal hyperplasia (E25.0)
        • hemolytic anemias attributable to enzyme disorders (D55.-)
        • Marfan's syndrome (Q87.4)
        • 5-alpha-reductase deficiency (E29.1)
        • androgen insensitivity syndrome (E34.5-)
        • congenital adrenal hyperplasia (E25.0)
        • hemolytic anemias attributable to enzyme disorders (D55.-)
        • Marfan syndrome (Q87.4-)
        • 5-alpha-reductase deficiency (E29.1)
  3. 2023

    No changes

  4. 2022

    Code changed

    • Type 1 excludes

        • androgen insensitivity syndrome (E34.5-)
        • congenital adrenal hyperplasia (E25.0)
        • Ehlers-Danlos syndromes (Q79.6-)
        • hemolytic anemias attributable to enzyme disorders (D55.-)
        • Marfan's syndrome (Q87.4)
        • 5-alpha-reductase deficiency (E29.1)
        • androgen insensitivity syndrome (E34.5-)
        • congenital adrenal hyperplasia (E25.0)
        • hemolytic anemias attributable to enzyme disorders (D55.-)
        • Marfan's syndrome (Q87.4)
        • 5-alpha-reductase deficiency (E29.1)
    • Type 2 excludes

        • Ehlers-Danlos syndromes (Q79.6-)
  5. 2021

    Code changed

    • Type 1 excludes

        • androgen insensitivity syndrome (E34.5-)
        • congenital adrenal hyperplasia (E25.0)
        • Ehlers-Danlos syndrome (Q79.6-)
        • hemolytic anemias attributable to enzyme disorders (D55.-)
        • Marfan's syndrome (Q87.4)
        • 5-alpha-reductase deficiency (E29.1)
        • androgen insensitivity syndrome (E34.5-)
        • congenital adrenal hyperplasia (E25.0)
        • Ehlers-Danlos syndromes (Q79.6-)
        • hemolytic anemias attributable to enzyme disorders (D55.-)
        • Marfan's syndrome (Q87.4)
        • 5-alpha-reductase deficiency (E29.1)
  6. 2020

    Code changed

    • Type 1 excludes

        • androgen insensitivity syndrome (E34.5-)
        • congenital adrenal hyperplasia (E25.0)
        • Ehlers-Danlos syndrome (Q79.6)
        • hemolytic anemias attributable to enzyme disorders (D55.-)
        • Marfan's syndrome (Q87.4)
        • 5-alpha-reductase deficiency (E29.1)
        • androgen insensitivity syndrome (E34.5-)
        • congenital adrenal hyperplasia (E25.0)
        • Ehlers-Danlos syndrome (Q79.6-)
        • hemolytic anemias attributable to enzyme disorders (D55.-)
        • Marfan's syndrome (Q87.4)
        • 5-alpha-reductase deficiency (E29.1)
  7. 2019

    No changes

  8. 2018

    No changes

  9. 2017

    No changes

  10. 2016

    New code